Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. Its pipeline includes CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 trials; velinotamig, a BCMAxCD3 bispecific T cell engager also in Phase 1 for autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager in Phase 1 for relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome. Additionally, the company is developing zipalertinib, an oral irreversible EGFR inhibitor in Phase 2b for EGFR ex20ins non-small cell lung cancer. Cullinan has license and co-development agreements with Chongqing Genrix Biopharmaceutical, Taiho Pharmaceutical, and Adimab.

Cullinan Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CGEM. Its shares are traded in United States Dollars (USD). The company is headquartered in Cambridge, Massachusetts, and operates primarily in the United States.

Cullinan Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing novel therapies for autoimmune diseases and cancer, leveraging bispecific T cell engagers and targeted inhibitors.

Cullinan Therapeutics is headquartered in Cambridge, Massachusetts, United States. The company primarily serves the U.S. market, as indicated by its description focusing on development activities in the United States. Its clinical trials and collaborations are centered in the U.S., though it has international partnerships, such as with Chongqing Genrix Biopharmaceutical in China and Taiho Pharmaceutical in Japan.

Cullinan Therapeutics' pipeline includes several key product candidates. CLN-978 is a CD19xCD3 bispecific T cell engager in Phase 1 for autoimmune diseases. Velinotamig, a BCMAxCD3 bispecific T cell engager, is also in Phase 1 for autoimmune diseases. CLN-049 targets FLT3xCD3 and is in Phase 1 for relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome. Zipalertinib, an oral irreversible EGFR inhibitor, is in Phase 2b for EGFR ex20ins non-small cell lung cancer. The company has a license agreement with Chongqing Genrix for velinotamig, a co-development agreement with Taiho for zipalertinib, and a collaboration with Adimab for antibody discovery.